A comprehensive view of Generics/Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Global generic drug market expected to grow to US$631.6B by 2027, with CAGR growth of 11.04% from 2022-2027; growth drivers include increase in chronic diseases, robust generic M&A activities, low cost of generics compared to branded drugs

PwC sees action-packed M&A landscape for pharmaceutical sector in H2, as drugmakers shore up pipelines in advance of generic competition coming this decade; 2022 will be a year of bolt-on transactions in US$5B-US$15B range, with potential for larger deals

Trends in generic drug market include drug makers to shift toward more complex generic drugs, continuation of reshoring of drug production; US government to support generic drug launches and generic prescriptions to manage rising costs: Fitch Solutions

Fresenius Kabi introduces generic injectable Thiotepa in US in 100 mg single-dose vials for treatment of breast or ovary adenocarcinoma; Thiotepa is generic equivalent of Tepadina

Teva swings to Q2 GAAP operating loss of US$949.0M from US$582.0M income last year, with revenues down 3% from a year ago to US$3.8B; generic, OTC business benefitted from easing of COVID-19 restrictions and firm reaches agreement in opioids litigation

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count